Is Incyte Corporation (INCY) a Buy, Sell, or Hold?
Incyte Corporation
NASDAQ:INCY
$114.88 USD
$0.65 (0.57%)
- Volume
- 1.3M
- Average Volume
- 1.73M
- Market Capitalization
- $22.95B
- P/E Ratio
- 15.74
- Dividend Yield
- 0.00%
- Price Target
- $108.50
- Year High
- $118.97
- Year Low
- $67.17
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.68
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | William J. Meury |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | INCY |
| CUSIP | 45337C102 |
| CIK | 0000879169 |
| Web | https://www.incyte.com |
| Phone | 302 498 6700 |
| Currency | USD |
| Employees | 2844 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.68 |
| Quick Ratio | 3.60 |
| Cash Ratio | 2.32 |
Sales & Book Value
| Annual Sales | $5.14B |
| Price / Sales | 4.28 |
| Cash Flow | 7.28 |
| Price / Cash Flow | 15.82 |
| Price / Book | 4.12 |
Price Target and Rating
| Average Stock Price Forecast | $108.50 |
| High Stock Price Forecast | $140.00 |
| Low Stock Price Forecast | $99.00 |
| Forecast Upside/Downside | 5.88% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 44 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $6.41 |
| Trailing P/E Ratio | 15.74 |
| PEG Ratio | 0.01 |
| P/E Growth | 0.01 |
| Net Income | $1.29B |
| Net Margin | 26.71% |
| Pretax Margin | 33.09% |
| Return on Equity | 29.31% |
| Return on Assets | 19.51% |
Financials Score
| AltmanZ Score | 9.94 |
| Piotroski Score | 5.00 |
| Working Capital | 3.99B |
| Total Assets | 7.34B |
| Ebit | 1.78B |
| Market Cap | 22.82B |
| Total Liabilities | 1.79B |
Poll Results
About Incyte Corporation (NASDAQ:INCY) Stock
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVH ... D. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
2026-07-13 04:00:00
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarciba
2026-07-13 04:00:00
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types.
2 Fast-Growing Pharmaceutical Stocks to Buy Now
2026-07-08 20:05:00
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.
Incyte to Report Second Quarter Financial Results
2026-07-08 08:00:00
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET Q2 2026 Conference Call: July 28, 2026, at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13759.
2026-07-06 08:39:00
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio.
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion
2026-07-03 11:58:35
Three outlier inflow signals push biopharmaceutical firm Incyte Corporation (INCY) up 71% in a year.
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
2026-06-29 14:41:13
Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
2026-06-29 10:55:55
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Frequently Asked Questions
-
What is the current Incyte Corporation (INCY) stock price?
-
Incyte Corporation(NASDAQ:INCY) stock price is $114.88 in the last trading session. During the trading session, INCY stock reached the peak price of $118.97 while $67.17 was the lowest point it dropped to. The percentage change in INCY stock occurred in the recent session was 0.57% while the dollar amount for the price change in INCY stock was $0.65.
-
INCY's industry and sector of operation?
-
The NASDAQ listed INCY is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of INCY?
-
Pamela Murphy | Vice President of Investor Relations & Corporate Communications
Xiaozhao Wang | Associate VP & Head of Medicinal Chemistry
Richard A. Hoffman | Executive VP, General Counsel & Secretary
Steven H. Stein | Executive VP, Head of Late-stage Development & Chief Medical Officer
Lee J. Heeson | Executive VP & Head of Incyte International -
How many employees does INCY have?
-
Number of INCY employees currently stands at 2844. INCY operates from 1801 Augustine Cut-Off, Wilmington, DE 19803, US.
-
Link for INCY official website?
-
Official Website of INCY is: https://www.incyte.com
-
How do I contact INCY?
-
INCY could be contacted at phone #302 498 6700 and can also be accessed through its website. INCY operates from 1801 Augustine Cut-Off, Wilmington, DE 19803, US.
-
How many shares of INCY are traded daily?
-
The average number of INCY shares traded daily for last 3 months was 1.73M.
-
What is the market cap of INCY currently?
-
The market value of INCY currently stands at $22.95B with its latest stock price at $114.88